Skip to main content
. Author manuscript; available in PMC: 2012 Jun 28.
Published in final edited form as: Radiat Res. 2010 Dec 28;175(3):297–306. doi: 10.1667/RR2399.1

FIG. 5.

FIG. 5

Panel A: Bone marrow plasma G-CSF levels after 8.5 Gy TBI. GT3, with or without PTX, induced an increase in bone marrow plasma G-CSF at day 0 and day 1 postirradiation. Panel B: Bone marrow plasma IL-1α levels after 8.5 Gy TBI. Treatment with GT3 in combination with PTX induced bone marrow plasma IL-1α levels at day 1 and day 10. Treatment with only GT3 did not increase IL-1α levels at day 1; however, it had an effect on day 10. Panel C: Bone marrow plasma IL-6 levels after 8.5 Gy TBI. IL-6 levels decreased after radiation exposure. GT3+PTX increased the availability of IL-6 at day 1 after TBI. GT3 did not affect IL-6. Panel D: Bone marrow plasma IL-9 levels after 8.5 Gy TBI. GT3+PTX increased the availability of IL-9 at day 1 after TBI. GT3 did not affect IL-9. Panel E: Bone marrow plasma GM-CSF levels after 8.5 Gy TBI. GM-CSF levels were decreased at day 1, 10 and 14 after radiation exposure. None of the treatments affected the postirradiation GM-CSF levels. Six mice per group from a single experiment (means ± SEM). *P < 0.05 compared to vehicle.